Cytokines

Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

Monday, October 19, 2020 - 7:00am

Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgens wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients.

Key Points: 
  • Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgens wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients.
  • Akron Biotech provides cGMP-compliant solutions to support the development and commercialization of advanced therapies.
  • Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgens formulation.
  • The agreement with Synairgen reflects our ongoing commitment to meet the growing demand for validated, cGMP-compliant solutions to advance novel therapies, said Claudia Zylberberg, PhD, Founder and CEO of Akron Biotech.

Viral 'molecular scissor' is next COVID-19 drug target: Coronavirus uses enzymatic cutter for virus production and to disable essential immune proteins

Sunday, October 18, 2020 - 12:10pm

The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.

Key Points: 
  • The researchers are from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and the Wroclaw University of Science and Technology.
  • Information gleaned by the American team helped Polish chemists to develop two molecules that inhibit the cutter, an enzyme called SARS-CoV-2-PLpro.
  • "It stimulates the release of proteins that are essential for the virus to replicate, and it also inhibits molecules called cytokines and chemokines that signal the immune system to attack the infection," Dr. Olsen said.
  • Visit our online Newsroom , and to see how we are battling COVID-19, read inspiring stories on Impact .

Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting

Thursday, October 15, 2020 - 1:00pm

4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.

Key Points: 
  • 4-1BBL is a costimulatory molecule that can drive T and NK cell proliferation and activation and interferon gamma (IFN) production.
  • IL-15 is a cytokine that bridges innate and adaptive immunity by promoting NK and T cell proliferation and NK cell cytotoxicity.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius Therapeutics manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News.

National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy

Tuesday, October 13, 2020 - 4:00pm

Humanigen is providing lenzilumab for the study, which is fully funded by NIH.

Key Points: 
  • Humanigen is providing lenzilumab for the study, which is fully funded by NIH.
  • ACTIV-5/BET is being conducted in collaboration with the NIHs public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines ( ACTIV ) program.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Angion to Present Multiple Posters at Kidney Week 2020

Friday, October 9, 2020 - 3:32pm

SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases today announced it will be presenting five posters at the American Society of Nephrologys Kidney Week 2020 virtual meeting to be held October 22-25, 2020.

Key Points: 
  • SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases today announced it will be presenting five posters at the American Society of Nephrologys Kidney Week 2020 virtual meeting to be held October 22-25, 2020.
  • ANG-3777 has a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury.
  • ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury.
  • Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach.

VirTrial Partners with BetterLife to Launch COVID-19 Clinical Trials

Friday, October 9, 2020 - 2:00pm

VirTrial today announced its selection by BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) as their telehealth platform provider of choice.

Key Points: 
  • VirTrial today announced its selection by BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) as their telehealth platform provider of choice.
  • The partnership will enable BetterLife to conduct remote patient monitoring for their imminent COVID-19 clinical trials in Australia to test the efficacy of AP-003, a proprietary interferon alpha 2b formulation.
  • VirTrial is a bioscience technology company providing a stable, long-standing telemedicine platform to transform the clinical trial industry.
  • The VirTrial platform combines secure video, audio, chat and messaging allowing pharmaceutical companies and CROs to create patient centric Decentralized Clinical Trials (DCTs) by replacing some study visits with virtual visits.

Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

Friday, October 9, 2020 - 12:00pm

Data will be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) on Friday, Oct. 9 at 9:00 AM ET (Poster #P2.20).

Key Points: 
  • Data will be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) on Friday, Oct. 9 at 9:00 AM ET (Poster #P2.20).
  • IRAK4 levels and the expression of proinflammatory cytokines are measured in skin biopsies obtained from lesional, peri-lesional and non-lesional skin and in blood.
  • The effect of KT-474 or an IRAK4 kinase inhibitor on IRAK4 levels and cytokine production are measured following ex vivo incubation of whole blood.
  • Poster #P2.20, Interim Results from Non-interventional Study to Evaluate Cutaneous and Circulating Biomarkers for a Novel IRAK4-Targeted Therapeutic in Patients with Hidradenitis Suppurativa, were presented by Dr. Alavi.

Global Hepatitis B Market Spotlight Report 2020: Aligos Deals Separately Target COVID-19, Hepatitis B - ResearchAndMarkets.com

Thursday, October 8, 2020 - 10:22am

The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.
  • Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, interferon receptor, interferon-alpha, and the immune system.
  • China leads in terms of the number of hepatitis B clinical trials globally, while Germany leads the major European markets.
  • GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for hepatitis B, followed by Gilead.

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO™ and Its Gene Delivery Platform

Tuesday, October 6, 2020 - 1:30pm

Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No.
  • "This new patent further strengthens our core intellectual property estate, broadening the exclusivity of OncoSec's novel combination drug-device platform for the intratumoral delivery of immune-stimulatory interleukins," said Keir Loiacono, General Counsel and Vice President, Corporate Development at OncoSec.
  • "The new IP serves to secure our competitive position in the intratumoral oncology space and builds on our patent portfolio of growing scope."
  • OncoSec's lead immunotherapy investigational product candidate TAVO (tavokinogene telseplasmid) enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.

Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Tuesday, September 22, 2020 - 9:30pm

Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), announced today that management will present a company overview and business update at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 10:50 a.m. EDT, Wednesday, September 23, 2020.

Key Points: 
  • Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), announced today that management will present a company overview and business update at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 10:50 a.m. EDT, Wednesday, September 23, 2020.
  • Archived replay will be available on the Company website for 30 days following the event.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.